Literature DB >> 11483269

Protection against influenza virus challenge by topical application of influenza DNA vaccine.

S Watabe1, K Q Xin, A Ihata, L J Liu, A Honsho, I Aoki, K Hamajima, B Wahren, K Okuda.   

Abstract

We studied the use of a DNA vaccine expressing the matrix (M) gene of the influenza virus A/PR/8/34. Mice were immunized by painting the DNA vaccine three times on the skin after removal of its keratinocytic layers. Immunization by this method produced M-specific antibodies and cytotoxic T lymphocyte (CTL) response, and acquired resistance against influenza virus challenge. This protection was abrogated by the in vivo injection of anti-CD8 or anti-CD4 monoclonal antibody. We further found that simultaneous topical application (t.a.) of GM-CSF expression plasmid (pGM-CSF) or liposomes plus mannan produced stronger immune response competence and enhanced the protective effect against influenza virus challenge. The present study revealed that administering DNA vaccine by topical application can elicit both humoral and cell-mediated immunity (CMI).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483269     DOI: 10.1016/s0264-410x(01)00194-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Topical application of plasmid DNA to mouse and human skin.

Authors:  Nuschin Meykadeh; Alireza Mirmohammadsadegh; Zhijun Wang; Etiena Basner-Tschakarjan; Ulrich R Hengge
Journal:  J Mol Med (Berl)       Date:  2005-05-19       Impact factor: 4.599

Review 3.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

4.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Authors:  Behazine Combadière; Annika Vogt; Brice Mahé; Dominique Costagliola; Sabrina Hadam; Olivia Bonduelle; Wolfram Sterry; Shlomo Staszewski; Hans Schaefer; Sylvie van der Werf; Christine Katlama; Brigitte Autran; Ulrike Blume-Peytavi
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

6.  Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus.

Authors:  Quanjiao Chen; Haimen Kuang; Huadong Wang; Fang Fang; Zhongdong Yang; Zhiping Zhang; Xianen Zhang; Ze Chen
Journal:  Virus Genes       Date:  2008-12-10       Impact factor: 2.332

7.  Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian; Khosrow Aghaiypour; Hassan Nili; Ali Mirjalili
Journal:  Mol Biol Rep       Date:  2009-10-07       Impact factor: 2.316

8.  A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.

Authors:  Haiyan Chang; Chaoyang Huang; Jian Wu; Fang Fang; Wenjie Zhang; Fuyan Wang; Ze Chen
Journal:  Virol J       Date:  2010-08-21       Impact factor: 4.099

9.  Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.

Authors:  Stephen Mark Tompkins; Zi-Shan Zhao; Chia-Yun Lo; Julia A Misplon; Teresa Liu; Zhiping Ye; Robert J Hogan; Zhengqi Wu; Kimberly A Benton; Terrence M Tumpey; Suzanne L Epstein
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

10.  Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin.

Authors:  Loree C Heller; Mark J Jaroszeski; Domenico Coppola; Richard Heller
Journal:  Genet Vaccines Ther       Date:  2008-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.